AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17673583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study 15705725 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal voluntary contractions at 30% of maximal voluntary contraction
Number of subjects: 17
Study 15705725 — intervention group
Group type: COMPARATOR
Intervention: Isometric reference contractions
Number of subjects: 17
Study 11817908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipids 20% energy diet + educational program (EP)
Number of subjects: 80
Study 11817908 — intervention group
Group type: COMPARATOR
Intervention: Lipids 30% energy diet (control group)
Number of subjects: 80
Study 10439009 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with azoospermia (n = 40)
Number of subjects: 40
Study 10439009 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Sertoli cell‐only syndrome (n = 36)
Number of subjects: 40
Study 10439009 — intervention group
Group type: COMPARATOR
Intervention: Control group (proven fathers n = 14 and healthy women n = 4)
Number of subjects: 40
Study 7541358 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 100 mg/day for 2 weeks
Number of subjects: 0
Study 7541358 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 100 mg/day for 4 weeks
Number of subjects: 0
Study 2087410 — intervention group
Group type: EXPERIMENTAL
Intervention: APF foam application
Number of subjects: 59
Study 2087410 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel application
Number of subjects: 59
Study 2087410 — intervention group
Group type: COMPARATOR
Intervention: Sponge-lined trays
Number of subjects: 59
Study 2087410 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlined trays
Number of subjects: 59
Study 2087410 — intervention group
Group type: EXPERIMENTAL
Intervention: First appointment with unlined trays
Number of subjects: 59
Study 2087410 — intervention group
Group type: EXPERIMENTAL
Intervention: Second appointment with unlined trays
Number of subjects: 59
Study 6106736 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 64
Study 6106736 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 64
Study 31999048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberball exclusion paradigm
Number of subjects: 32
Study 31999048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberball overinclusion paradigm
Number of subjects: 32
Study 31999048 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study 29236526 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-color graphic warning labels (GWLs)
Number of subjects: 653
Study 29236526 — intervention group
Group type: EXPERIMENTAL
Intervention: Black-and-white graphic warning labels (GWLs)
Number of subjects: 653
Study 29236526 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels (either color or black-and-white)
Number of subjects: 653
Study 29236526 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-only labels
Number of subjects: 653
Study 29236526 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels and text-only labels
Number of subjects: 653
Study 29236526 — intervention group
Group type: COMPARATOR
Intervention: Brand imagery only
Number of subjects: 653
Study 27321197 — intervention group
Group type: COMPARATOR
Intervention: Glasses with power determined by subjective cycloplegic retinoscopy by a university optometrist (U)
Number of subjects: 426
Study 27321197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (RM)
Number of subjects: 426
Study 27321197 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses with power determined by a rural refractionist (R)
Number of subjects: 426
Study 27321197 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses with power determined by non-cycloplegic self-refraction (SR)
Number of subjects: 426
Study 25793635 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural monopolar galvanic vestibular stimulation (GVS)
Number of subjects: 7
Study 25793635 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 7
Study 24512246 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Anxiety Disorder (SAD) group
Number of subjects: 86
Study 24512246 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86
Study 22440336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib plus erlotinib
Number of subjects: 0
Study 22440336 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 0
Study 19352169 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 101
Study 19352169 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 101
Study 17898251 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl citrate (1.5 microg/kg)
Number of subjects: 41
Study 17898251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl citrate (3.0 microg/kg)
Number of subjects: 41
Study 15115681 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphur baths
Number of subjects: 40
Study 15115681 — intervention group
Group type: COMPARATOR
Intervention: control group (spa therapy alone)
Number of subjects: 40
Study 11641670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg)
Number of subjects: 325
Study 11641670 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (20 units)
Number of subjects: 325
Study 9853762 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin depot treatment for 12 weeks before hysterectomy
Number of subjects: 127
Study 9853762 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 127
Study 8003098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol esters (< 1 g/day of free sterols) dissolved in rapeseed oil (RSO)
Number of subjects: 0
Study 8003098 — intervention group
Group type: COMPARATOR
Intervention: RSO diet (control group)
Number of subjects: 0
Study 2786179 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz, 250 msec TENS
Number of subjects: 60
Study 2786179 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz, 50 msec TENS
Number of subjects: 60
Study 2786179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain suppressor TENS
Number of subjects: 60
Study 2786179 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz, 250 msec TENS
Number of subjects: 60
Study 2786179 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 60
Study 2786179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure algometer assessment
Number of subjects: 60
Study 1118088 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuril, 500 mg/day
Number of subjects: 75
Study 1118088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilantin, 100 mg, t.i.d.
Number of subjects: 75
Study 1118088 — intervention group
Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 75
Study 31825926 — intervention group
Group type: EXPERIMENTAL
Intervention: Li‐ESWT treatment (4 sessions on the PiezoWave2 unit)
Number of subjects: 60
Study 30252774 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (1.83 g protein·kg·d)
Number of subjects: 10
Study 30252774 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (1.20 g protein·kg·d)
Number of subjects: 10
Study 30252774 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (0.94 g protein·kg·d)
Number of subjects: 10
Study 27761704 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft (LCAG) with intraoperative 0.02% mitomycin C (MMC) for 3 min
Number of subjects: 96
Study 27761704 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG) with intraoperative 0.02% mitomycin C (MMC) for 3 min
Number of subjects: 96
Study 27761704 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft (LCAG)
Number of subjects: 96
Study 27761704 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG)
Number of subjects: 96
Study 27761704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 25630442 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive interaction between Agents A and B
Number of subjects: 0
Study 25630442 — intervention group
Group type: EXPERIMENTAL
Intervention: B hitting Agent C while A was absent
Number of subjects: 0
Study 25630442 — intervention group
Group type: EXPERIMENTAL
Intervention: A witnessing B's harmful action
Number of subjects: 0
Study 25630442 — intervention group
Group type: EXPERIMENTAL
Intervention: B accidentally hitting C while A was present
Number of subjects: 0
Study 21593284 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Wings Girls' Groups (16-session facilitated curriculum including sharing circles, mind-body exercises, and coping skills building)
Number of subjects: 42
Study 21593284 — intervention group
Group type: COMPARATOR
Intervention: Attention control (similar format but focused on general health topics)
Number of subjects: 42
Study 22168590 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin threshold of 10 g/dL)
Number of subjects: 2016
Study 22168590 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (hemoglobin level <8 g/dL or symptoms of anemia at physician discretion)
Number of subjects: 2016
Study 22168590 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 2016
Study 22168590 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 2016
Study 19917850 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction biochemotherapy (cisplatin, vinblastine, dacarbazine, decrescendo IL-2, interferon alfa-2b, GM-CSF)
Number of subjects: 133
Study 19917850 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance biotherapy (low-dose IL-2 and GM-CSF followed by intermittent pulses of decrescendo IL-2 over 12 months)
Number of subjects: 133
Study 19917850 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS progression
Number of subjects: 133
Study 16825703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated red grape juice (RGJ) 100 mL/d for 14 days
Number of subjects: 41
Study 16825703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated red grape juice (RGJ) for 3 weeks in hemodialysis patients
Number of subjects: 41
Study 16825703 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 hemodialysis patients not receiving RGJ)
Number of subjects: 41
Study 15273015 — intervention group
Group type: EXPERIMENTAL
Intervention: Self and close others
Number of subjects: 0
Study 15273015 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal closeness
Number of subjects: 0
Study 11404812 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific and high goal
Number of subjects: 109
Study 11404812 — intervention group
Group type: COMPARATOR
Intervention: Do your best goal
Number of subjects: 109
Study 9060852 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 171
Study 9060852 — intervention group
Group type: COMPARATOR
Intervention: Low‐flow cardiopulmonary bypass (LFB)
Number of subjects: 171
Study 9060852 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG seizures
Number of subjects: 171
Study 9060852 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with EEG seizures
Number of subjects: 171
Study 8351678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro‐Intestinal‐Therapeutic‐Systems (GITS) 2.5 mg (Treatment B)
Number of subjects: 24
Study 8351678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro‐Intestinal‐Therapeutic‐Systems (GITS) 5 mg (Treatment C)
Number of subjects: 24
Study 8351678 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablets (3 x 1 mg) (Treatment A)
Number of subjects: 24
Study 8351678 — intervention group
Group type: COMPARATOR
Intervention: Traditional sustained release formulation (4 mg) (Treatment D)
Number of subjects: 24
Study 3826577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 1100
Study 3826577 — intervention group
Group type: COMPARATOR
Intervention: Meptazinol
Number of subjects: 1100
Study 3826577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Pethidine and Meptazinol)
Number of subjects: 1100
Study 30045702 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Number of subjects: 0
Study 30045702 — intervention group
Group type: COMPARATOR
Intervention: Relaxation condition (active therapy control)
Number of subjects: 0
Study 30045702 — intervention group
Group type: COMPARATOR
Intervention: Standard of care risk reduction counseling
Number of subjects: 0
Study 27064671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections
Number of subjects: 9
Study 27064671 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injections
Number of subjects: 9
Study 24039182 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor
Number of subjects: 0
Study 24039182 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG
Number of subjects: 0
Study 22183086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 IU/day)
Number of subjects: 23
Study 22183086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22183086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation and Placebo (combined)
Number of subjects: 23
Study 20508467 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight+plyometrics+EMS (EP)
Number of subjects: 29
Study 20508467 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight+plyometrics (VP)
Number of subjects: 29
Study 20508467 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study 20508467 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study 18448328 — intervention group
Group type: COMPARATOR
Intervention: FUOX (fluorouracil/oxaliplatin)
Number of subjects: 110
Study 18448328 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable genotypes (0, 1, or 2 FG)
Number of subjects: 110
Study 18448328 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable genotypes (2 FG)
Number of subjects: 110
Study 18448328 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1-118
Number of subjects: 110
Study 18448328 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-3'UTR
Number of subjects: 110
Study 16979511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 33
Study 16979511 — intervention group
Group type: COMPARATOR
Intervention: Dry-towel massage
Number of subjects: 33
Study 16979511 — intervention group
Group type: COMPARATOR
Intervention: Presence
Number of subjects: 33
Study 14513919 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine coadministered with clonazepam followed by a tapered benzodiazepine discontinuation phase (PC-D)
Number of subjects: 60
Study 14513919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing combination treatment (PC-M)
Number of subjects: 60
Study 14513919 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine and placebo (PP)
Number of subjects: 60
Study 11069324 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d., josamycin 1000 mg b.d. and famotidine 20 mg b.d. (BFJF group)
Number of subjects: 120
Study 11069324 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. (BFC group)
Number of subjects: 120
Study 11069324 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (BFJF group)
Number of subjects: 120
Study 11069324 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (BFC group)
Number of subjects: 120
Study 9081105 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuits (Duraflo II, n = 13)
Number of subjects: 26
Study 9081105 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass circuits (n = 13)
Number of subjects: 26
Study 9081105 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cardiopulmonary bypass
Number of subjects: 26
Study 8228636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol esters (3.4 g/day)
Number of subjects: 67
Study 8228636 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed oil (control)
Number of subjects: 67
Study 8228636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol esters
Number of subjects: 67
Study 3511706 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (500 mg intravenously)
Number of subjects: 46
Study 3511706 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 46
Study 29741230 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management program (www.selfmanagescleroderma.com)
Number of subjects: 267
Study 29741230 — intervention group
Group type: COMPARATOR
Intervention: Patient-focused educational book
Number of subjects: 267
Study 29741230 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management program
Number of subjects: 267
Study 29998337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase at standard dose (0.9 mg/kg) with oral placebo (n=156)
Number of subjects: 948
Study 29998337 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin, 325 mg, with intravenous placebo (n=157)
Number of subjects: 948
Study 29998337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 948
Study 29998337 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin
Number of subjects: 948
Study 27602507 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 408
Study 27602507 — intervention group
Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 408
Study 25096595 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirschner wire fixation
Number of subjects: 461
Study 25096595 — intervention group
Group type: COMPARATOR
Intervention: Locking plate fixation
Number of subjects: 461
Study 22730101 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) administered intravenously every 3-4 weeks
Number of subjects: 0
Study 22730101 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 22730101 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 0
Study 20864814 — intervention group
Group type: EXPERIMENTAL
Intervention: JE/YF sequential vaccination
Number of subjects: 108
Study 20864814 — intervention group
Group type: EXPERIMENTAL
Intervention: YF/JE sequential vaccination
Number of subjects: 108
Study 20864814 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of JE and YF
Number of subjects: 108
Study 20864814 — intervention group
Group type: EXPERIMENTAL
Intervention: YF vaccine
Number of subjects: 108
Study 20864814 — intervention group
Group type: EXPERIMENTAL
Intervention: JE vaccine
Number of subjects: 108
Study 17013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (including 70 radical prostatectomy, 24 radiation, 10 endocrine treatment)
Number of subjects: 270
Study 17013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (specifically radical prostatectomy)
Number of subjects: 270
Study 17013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PSADT < 2 years
Number of subjects: 270
Study 17013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PSADT > 4 years
Number of subjects: 270
Study 17013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PSADT
Number of subjects: 270
Study 17013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 270
Study 15334433 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (200 mg/day)
Number of subjects: 28
Study 15334433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11165427 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 188
Study 11165427 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures of mediastinoscopy or thoracotomy
Number of subjects: 188
Study 9545145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWH)
Number of subjects: 0
Study 9545145 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agents (aspirin and ticlopidine)
Number of subjects: 0
Study 8138522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8138522 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) 2.5 mg/kg
Number of subjects: 18
Study 8138522 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 18
Study 2591079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment under a hydrocolloid occlusive dressing
Number of subjects: 8
Study 2591079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4299208 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved immunosuppression and better organ preservation in later cases (after July 1967)
Number of subjects: 17
Study 4299208 — intervention group
Group type: COMPARATOR
Intervention: Liver homografts with no specific intervention mentioned
Number of subjects: 17
Study 30182376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (health workers trained according to national guidelines)
Number of subjects: 617
Study 30182376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 617
Study 28219619 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing plus facility-based testing
Number of subjects: 362
Study 26887211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation of acupoints of the Conception Vessel, Kidney Meridian, Spleen Meridian, and Bladder Meridian
Number of subjects: 96
Study 26887211 — intervention group
Group type: COMPARATOR
Intervention: Estradiol Valerate tablets and Estradiol Cyproterone
Number of subjects: 96
Study 26887211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 96
Study 26887211 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 96